RA
RAPT Therapeutics, Inc.
RAPT · NASDAQ
$58.01 +0.00% (+$0.00)
Market Cap $959.3M
P/E Ratio -
Div. Yield -
ROE 61.81%
Bulios Fair Price
$47.07
18.9% downside
Current Price
$58.01
Undervalued Fair Value Overvalued
According to Bulios Fair Price, RAPT is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Analysis
An AI report on the business, its finances, valuation, sentiment, news and risks - written in a few minutes.
Piotroski F-Score Weak
2/9Valuation
21 /100
Expensive P/B 6.31x
EV/FFO N/A
P/E N/A
Growth
100 /100
Growing Book val. growth 49.67%
FCF growth N/A
EPS growth N/A
Profitability
-
N/A Op. margin N/A
Gross margin N/A
FCF margin N/A
Quality
0 /100
Poor ROA 63.74%
ROIC 72.87%
Asset turnover 0.00x
Debt
100 /100
Low Net debt/EBITDA 0.33x
Debt/Equity 0.02x
Current ratio 12.04x
Stability
23 /100
Unstable Profitable years 0
Beta 0.44x
EPS volatility 471.36%
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about RAPT
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Brian Russell Wong
Employees
67
Headquarters
South San Francisco